Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children

S. Jayasinghe; C. Chiu; R. Menzies; Deborah Lehmann; H. Cook; C. Giele; V. Krause; P. Mcintyre

doi:10.1016/j.vaccine.2015.10.089

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children

S. Jayasinghe, C. Chiu, R. Menzies, Deborah Lehmann, H. Cook, C. Giele, V. Krause, P. Mcintyre

UWA Centre for Child Health Research (affiliated with the The Kids Research Institute Australia)

Research output: Contribution to journal › Article › peer-review

14 Citations (Web of Science)

Abstract

© 2015 Elsevier Ltd. Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Methods: Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children

Original language	English
Pages (from-to)	6666-6674
Journal	Vaccine
Volume	33
Issue number	48
DOIs	https://doi.org/10.1016/j.vaccine.2015.10.089
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2015.10.089

Cite this

@article{6b5f56d1f1bc4557af797e75f4d6b982,

title = "Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children",

abstract = "{\textcopyright} 2015 Elsevier Ltd. Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Methods: Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children",

author = "S. Jayasinghe and C. Chiu and R. Menzies and Deborah Lehmann and H. Cook and C. Giele and V. Krause and P. Mcintyre",

year = "2015",

doi = "10.1016/j.vaccine.2015.10.089",

language = "English",

volume = "33",

pages = "6666--6674",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "48",

}

TY - JOUR

T1 - Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children

AU - Jayasinghe, S.

AU - Chiu, C.

AU - Menzies, R.

AU - Lehmann, Deborah

AU - Cook, H.

AU - Giele, C.

AU - Krause, V.

AU - Mcintyre, P.

PY - 2015

Y1 - 2015

N2 - © 2015 Elsevier Ltd. Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Methods: Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children

AB - © 2015 Elsevier Ltd. Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Methods: Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children

U2 - 10.1016/j.vaccine.2015.10.089

DO - 10.1016/j.vaccine.2015.10.089

M3 - Article

C2 - 26519550

SN - 0264-410X

VL - 33

SP - 6666

EP - 6674

JO - Vaccine

JF - Vaccine

IS - 48

ER -

Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this